Ivermectin Orion: Uses, Dosage & Side Effects
An antiparasitic medication (avermectin derivative) used to treat strongyloidiasis, onchocerciasis, and other parasitic infections
Ivermectin Orion is an antiparasitic medication containing ivermectin, a broad-spectrum avermectin derivative that has been a cornerstone of tropical and parasitic medicine since its introduction in the 1980s. It is primarily used to treat intestinal strongyloidiasis (caused by the nematode Strongyloides stercoralis) and onchocerciasis (river blindness, caused by Onchocerca volvulus). Ivermectin is also used for other parasitic conditions including lymphatic filariasis, scabies, and certain ectoparasitic infections. Available as 3 mg oral tablets, it is typically administered as a single-dose or short-course treatment calculated by body weight. Ivermectin is included on the WHO Model List of Essential Medicines and is one of the most widely used antiparasitic drugs globally.
Quick Facts: Ivermectin Orion
Key Takeaways
- Ivermectin Orion is an essential antiparasitic medication that works by paralysing and killing parasites through disruption of their nerve and muscle function via glutamate-gated chloride channels.
- It is primarily prescribed for intestinal strongyloidiasis and onchocerciasis (river blindness), and is also effective against scabies, lymphatic filariasis, and certain other parasitic infections.
- The standard dose is approximately 200 micrograms per kilogram of body weight, taken as a single dose on an empty stomach; food significantly increases absorption and may alter the drug’s therapeutic effect.
- Special caution is required in patients co-infected with Loa loa (African eye worm), as treatment may trigger a potentially fatal encephalopathy due to rapid killing of microfilariae in the central nervous system.
- Ivermectin is not recommended for children weighing less than 15 kg, should be used with caution during pregnancy and breastfeeding, and requires a prescription in most countries worldwide.
What Is Ivermectin Orion and What Is It Used For?
Ivermectin Orion contains the active substance ivermectin, which belongs to the avermectin class of antiparasitic agents. Ivermectin was originally discovered in the late 1970s as a fermentation product of the soil bacterium Streptomyces avermitilis. Its discovery and development led to the 2015 Nobel Prize in Physiology or Medicine, shared by William C. Campbell and Satoshi Omura, in recognition of its extraordinary impact on global public health. Since its introduction for human use in 1987, ivermectin has been administered to hundreds of millions of people worldwide, principally through mass drug administration (MDA) programmes for the control of onchocerciasis and lymphatic filariasis in endemic regions.
The mechanism of action of ivermectin is highly selective for invertebrate organisms. Ivermectin binds with high affinity to glutamate-gated chloride (GluCl) ion channels, which are found in invertebrate nerve and muscle cells but are absent in mammals. This binding increases the permeability of the cell membrane to chloride ions, leading to hyperpolarisation of the nerve or muscle cell. The resulting sustained inhibition of neuromuscular activity causes paralysis and death of the parasite. Ivermectin also interacts with other ligand-gated chloride channels, including those gated by gamma-aminobutyric acid (GABA), though this interaction is less potent. In mammals, these GABA-gated channels are primarily found in the central nervous system (CNS) and are normally protected by the blood-brain barrier, which explains the selective toxicity of ivermectin to parasites rather than the human host.
Ivermectin Orion is approved for use in the following parasitic infections:
- Intestinal strongyloidiasis: Infection caused by the nematode Strongyloides stercoralis, which can persist in the intestines for decades through an autoinfection cycle. Ivermectin is considered the treatment of choice for this condition, with cure rates of 83–100% after one or two doses, significantly superior to older treatments such as albendazole or thiabendazole.
- Onchocerciasis (river blindness): A filarial disease caused by Onchocerca volvulus, transmitted by blackflies. Ivermectin effectively kills the microfilariae (larval stage) but not the adult worms, necessitating repeated treatment every 6–12 months. Onchocerciasis remains a leading infectious cause of blindness globally, affecting approximately 21 million people, mainly in sub-Saharan Africa.
- Lymphatic filariasis: Caused by Wuchereria bancrofti, Brugia malayi, or Brugia timori. Ivermectin is used in combination with albendazole (and sometimes diethylcarbamazine) in mass drug administration programmes aimed at eliminating this neglected tropical disease. It is particularly effective at reducing microfilarial levels.
- Scabies: Infestation by the mite Sarcoptes scabiei. While topical permethrin is often first-line therapy, oral ivermectin is increasingly used, especially for crusted (Norwegian) scabies, institutional outbreaks, and cases resistant to topical treatments. A single dose of 200 mcg/kg is typically given, with a repeat dose after 7–14 days.
- Other parasitic infections: Ivermectin may also be used off-label for conditions such as cutaneous larva migrans, gnathostomiasis, pediculosis (head lice), and certain other helminthic infections, depending on local guidelines and prescriber judgement.
It is important to note that ivermectin acts primarily against the microfilarial (larval) stages of filarial parasites rather than the adult worms. For onchocerciasis, this means that treatment reduces the disease burden and prevents new eye and skin damage, but does not cure the infection, since adult worms can survive for 10–15 years in subcutaneous nodules. Regular repeated dosing is therefore necessary to maintain suppression of microfilariae and prevent disease progression.
Ivermectin is listed on the World Health Organization’s Model List of Essential Medicines, reflecting its critical importance in global health. Through the Mectizan Donation Program, more than 4 billion treatments have been donated since 1987, contributing to the near-elimination of river blindness in several countries. Ivermectin is considered one of the most significant contributions to human health in the 20th century.
What Should You Know Before Taking Ivermectin Orion?
Contraindications
There are specific situations in which Ivermectin Orion must not be used. Understanding these contraindications is essential before treatment begins.
- Hypersensitivity: Do not take Ivermectin Orion if you are allergic to ivermectin or any of the other ingredients in the tablet (such as microcrystalline cellulose, pregelatinised maize starch, citric acid monohydrate, butylated hydroxyanisole, or magnesium stearate). Allergic reactions, while rare, can include rash, urticaria, and in very rare cases, anaphylaxis.
- Children weighing less than 15 kg: The safety and efficacy of ivermectin have not been established in children weighing less than 15 kg. The 3 mg tablet formulation is not suitable for accurate dosing in this population.
Warnings and Precautions
Patients who may have been exposed to Loa loa (African eye worm), particularly those from or having lived in Central and West Africa, must be screened before receiving ivermectin. The rapid killing of Loa loa microfilariae by ivermectin can trigger a serious and potentially fatal encephalopathy, especially when microfilarial loads are high (typically >30,000 microfilariae/mL). Symptoms include confusion, lethargy, coma, and death. If treatment is necessary in these patients, it should be carried out in a hospital setting with close monitoring.
Before and during treatment with Ivermectin Orion, inform your doctor if any of the following apply to you:
- Mazzotti reaction (onchocerciasis patients): In patients being treated for onchocerciasis, the death of microfilariae can trigger an inflammatory response known as the Mazzotti reaction. This may manifest as fever, itching, rash, swelling, joint and muscle pain, swollen lymph nodes, tachycardia, hypotension, and in severe cases respiratory distress. The reaction is not an allergy to ivermectin itself but rather an immune response to the dying parasites. It typically occurs within 1–3 days of treatment and usually resolves within a few days. Supportive care with analgesics, antihistamines, or corticosteroids may be needed. In areas where onchocerciasis is endemic, patients should be monitored after treatment.
- Hyperinfection with Strongyloides: In immunocompromised patients (e.g., those taking corticosteroids or other immunosuppressants, or those with HTLV-1 co-infection), Strongyloides stercoralis can cause a hyperinfection syndrome or disseminated disease, which can be life-threatening. While ivermectin is the treatment of choice, these patients may require prolonged or repeated courses and close monitoring. Immunosuppressive therapy should be minimised where possible.
- Liver disease: Ivermectin is extensively metabolised by the liver (primarily via CYP3A4). Patients with significant hepatic impairment may have altered drug metabolism and exposure. Dosing adjustments may be necessary, and liver function should be monitored.
- CNS disorders and blood-brain barrier integrity: Although ivermectin does not normally cross the intact blood-brain barrier in significant amounts, patients with conditions that may compromise the blood-brain barrier (e.g., meningitis, African trypanosomiasis, or concurrent use of drugs that increase blood-brain barrier permeability) may be at increased risk of CNS toxicity. Signs include confusion, tremor, ataxia, and somnolence.
- Asthma: In patients with asthma, the death of certain parasites (particularly in helminthic infections of the lungs) can occasionally trigger bronchospasm. Caution is advised.
- Driving and machinery: Ivermectin may cause dizziness or somnolence. If you experience these effects, do not drive or operate machinery until the symptoms have resolved.
Pregnancy and Breastfeeding
Ivermectin Orion should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the foetus. Animal reproductive studies have shown that ivermectin can cause adverse developmental effects at high doses (cleft palate in mice, reduced foetal weight in rats and rabbits at maternally toxic doses). However, there is limited data from human pregnancies. Epidemiological data from mass drug administration programmes, where women were inadvertently treated in early pregnancy, have not shown a clear increase in the rate of congenital malformations, but the data are insufficient to definitively exclude risk.
Ivermectin is excreted in human breast milk in low concentrations. Although adverse effects in breastfed infants are considered unlikely at therapeutic doses, caution is advised. In mass drug administration settings, the WHO generally recommends deferring treatment in women who are breastfeeding infants less than one week old. For individual treatment decisions, discuss the risks and benefits with your doctor.
Women of childbearing potential should be advised to use effective contraception during treatment. If you discover you are pregnant during or shortly after treatment, inform your doctor promptly.
Always inform your doctor about all medical conditions, medications, and supplements you are taking before starting Ivermectin Orion. This includes over-the-counter medicines, herbal remedies, and vitamins. Some medications can interact with ivermectin and alter its effects.
How Does Ivermectin Orion Interact with Other Drugs?
Drug interactions with ivermectin primarily involve the cytochrome P450 3A4 (CYP3A4) enzyme system, which is the main pathway responsible for the hepatic metabolism of the drug. Medications that alter the activity of CYP3A4 can therefore influence the plasma concentrations of ivermectin, potentially affecting both its efficacy and safety profile. Ivermectin is also a substrate of P-glycoprotein (P-gp), an efflux transporter that plays a critical role in limiting drug distribution across the blood-brain barrier. Drugs that inhibit P-gp may increase ivermectin levels in the CNS and potentially lead to neurotoxic effects.
It is essential to inform your doctor about all medications, supplements, and herbal products you are taking before starting treatment with Ivermectin Orion.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Warfarin | Enhanced anticoagulant effect; increased INR and risk of bleeding | Monitor INR closely if co-administered; dose adjustment of warfarin may be necessary |
| Diethylcarbamazine (DEC) | Combined rapid microfilarial killing; increased risk of severe inflammatory reactions in Loa loa co-infection | Do not co-administer in areas endemic for Loa loa without screening |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) | Increased ivermectin plasma levels; enhanced risk of adverse effects | Use with caution; monitor for increased side effects; dose reduction may be considered |
| Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) | Decreased ivermectin plasma levels; potentially reduced efficacy | Avoid combination if possible; therapeutic response should be carefully monitored |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Moderate CYP3A4 inhibitors (erythromycin, diltiazem, grapefruit juice) | Possible modest increase in ivermectin plasma levels | Monitor for increased side effects; consider avoiding large amounts of grapefruit juice |
| P-glycoprotein inhibitors (verapamil, quinidine, cyclosporine) | Potential increase in ivermectin CNS penetration; increased risk of neurotoxicity | Use with caution; monitor for CNS symptoms such as confusion, tremor, or ataxia |
| Albendazole | Synergistic antiparasitic effect; no significant pharmacokinetic interaction | Combination is used intentionally in mass drug administration for lymphatic filariasis |
| Alcohol | May enhance CNS depressant effects (dizziness, somnolence) | Advise patients to limit alcohol consumption during treatment |
Although ivermectin has relatively few clinically significant drug interactions compared with many other medications, the potential for interactions via CYP3A4 and P-glycoprotein pathways means that careful medication review is always warranted. Patients taking multiple medications, particularly those with hepatic impairment, should have their treatment supervised by a physician experienced in the use of antiparasitic drugs.
What Is the Correct Dosage of Ivermectin Orion?
Ivermectin Orion is available as 3 mg tablets. The dose is calculated individually based on the patient’s body weight. Tablets should be swallowed whole with water on an empty stomach – at least 2 hours before or after food. Taking ivermectin with a high-fat meal can significantly increase absorption (by approximately 2.5-fold), which may alter the drug’s therapeutic and safety profile. Unless specifically directed by your physician, always take ivermectin on an empty stomach to ensure consistent and predictable drug levels.
Adults
| Indication | Dose | Schedule |
|---|---|---|
| Strongyloidiasis | 200 mcg/kg as a single dose | Single dose; repeat after 2 weeks if not cured. For hyperinfection: repeat until negative stool tests |
| Onchocerciasis | 150 mcg/kg as a single dose | Repeat every 6–12 months for as long as adult worms survive (up to 10–15 years) |
| Scabies | 200 mcg/kg as a single dose | Repeat after 7–14 days (two doses total); for crusted scabies: up to 3–7 doses combined with topical treatment |
| Lymphatic filariasis (MDA) | 150–200 mcg/kg as a single dose | Annual single dose, usually combined with albendazole |
For practical purposes, the following weight-based dosing guide is commonly used for the standard 200 mcg/kg dose with 3 mg tablets:
| Body Weight | Number of 3 mg Tablets | Total Dose |
|---|---|---|
| 15–24 kg | 1 tablet | 3 mg |
| 25–35 kg | 2 tablets | 6 mg |
| 36–50 kg | 3 tablets | 9 mg |
| 51–65 kg | 4 tablets | 12 mg |
| 66–79 kg | 5 tablets | 15 mg |
| ≥80 kg | 6 tablets (or as directed) | 18 mg (or as directed) |
Children
Ivermectin Orion is not recommended for children weighing less than 15 kg, as the safety and efficacy have not been established in this population. For children weighing 15 kg or more, the dose is calculated in the same way as for adults (200 mcg/kg for strongyloidiasis and scabies; 150 mcg/kg for onchocerciasis), using the weight-based dosing table above. The 3 mg tablet formulation allows for practical dose calculation in children above the 15 kg threshold.
Special care should be taken when treating children, as they may be more susceptible to certain adverse effects. Treatment should always be supervised by a healthcare professional experienced in the management of parasitic infections in paediatric patients.
Elderly
No specific dose adjustment is generally required for elderly patients. However, elderly individuals are more likely to have hepatic or renal impairment and may be taking multiple medications that could interact with ivermectin. Careful assessment of liver function, concomitant medications, and overall clinical status is recommended before prescribing ivermectin in this population. The risk of dizziness and postural hypotension may also be higher in elderly patients.
Missed Dose
Ivermectin is typically given as a single dose or a very short course (e.g., two doses separated by 1–2 weeks for scabies). If a scheduled repeat dose is missed, take it as soon as you remember unless it is close to the time for the next planned dose. Do not take a double dose to make up for a missed one. Contact your doctor or pharmacist for advice if you are unsure when to take a missed dose.
Overdose
In cases of accidental or intentional overdose with ivermectin, symptoms may include rash, urticaria, oedema, headache, dizziness, asthenia (weakness), nausea, vomiting, diarrhoea, abdominal pain, seizures, ataxia, dyspnoea, and paresthesia. Treatment is supportive, as there is no specific antidote for ivermectin. Gastric lavage or administration of activated charcoal may be considered if the ingestion was recent (within 1–2 hours). Patients should be monitored in a clinical setting, with particular attention to respiratory function and neurological status. In cases of significant overdose, the effects are usually self-limiting due to the relatively wide therapeutic index of ivermectin.
Always take Ivermectin Orion tablets on an empty stomach with a full glass of water. Food – particularly fatty food – significantly increases absorption and may alter the drug’s effect. Wait at least 2 hours after taking the tablets before eating.
What Are the Side Effects of Ivermectin Orion?
Like all medicines, Ivermectin Orion can cause side effects, although not everybody gets them. The nature and frequency of side effects can vary depending on the parasitic infection being treated, as many of the reactions observed – particularly during treatment of filarial infections – are related to the host immune response to dying parasites rather than direct drug toxicity. This distinction is clinically important.
When ivermectin is used for intestinal strongyloidiasis in otherwise healthy patients, the drug is generally very well tolerated. Side effects tend to be mild and transient. When used for onchocerciasis, however, the Mazzotti reaction (an inflammatory response to dying microfilariae) is common, particularly on first exposure, and can range from mild to severe.
The following side effects have been reported with ivermectin use. These frequencies are based on clinical trial data and post-marketing surveillance across all approved indications:
Very Common
Affects more than 1 in 10 patients
- Mazzotti reaction in onchocerciasis patients (fever, pruritus/itching, rash, arthralgia, myalgia, lymphadenopathy, tachycardia, hypotension)
Common
Affects 1 in 10 to 1 in 100 patients
- Dizziness
- Somnolence (drowsiness)
- Nausea
- Diarrhoea
- Abdominal pain
- Decreased appetite
- Asthenia (weakness/fatigue)
- Transient eosinophilia (increase in white blood cells)
- Elevated liver enzymes (ALT, AST)
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Headache
- Tremor
- Vertigo
- Constipation
- Rash or urticaria (not Mazzotti-related)
- Pruritus (not related to parasite death)
- Tachycardia
- Transient hypotension (low blood pressure)
- Peripheral or facial oedema (swelling)
Rare
Affects fewer than 1 in 1,000 patients
- Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN)
- Hepatotoxicity (liver injury, including hepatitis)
- Seizures
- Encephalopathy (particularly in Loa loa co-infection)
- Visual disturbances or worsening of eye disease (in onchocerciasis)
- Haematuria (blood in urine)
Not Known
Frequency cannot be estimated from available data
- Serious hypersensitivity reactions including anaphylaxis
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Worsening of bronchial asthma
The Mazzotti reaction deserves special attention. When ivermectin is used to treat onchocerciasis, the death of microfilariae in the skin, eyes, and lymph nodes triggers a host inflammatory response that can be quite dramatic. The intensity of the reaction is generally proportional to the microfilarial load – patients with higher burdens of infection are more likely to experience severe reactions. The reaction typically peaks within 1–3 days after treatment and resolves within 5–7 days. Supportive treatment with antipyretics, antihistamines, and in severe cases corticosteroids may be required. First-time treatments tend to produce more intense reactions than subsequent doses, as the microfilarial load progressively decreases with each treatment cycle.
It is important to note that when ivermectin is used for strongyloidiasis or scabies in patients without concurrent filarial infections, the side effect profile is typically very mild. Most patients experience no adverse effects at all, or only mild and transient gastrointestinal symptoms.
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed above. You can also report side effects directly to your national pharmacovigilance authority to help provide more information on the safety of this medicine.
How Should You Store Ivermectin Orion?
Proper storage of medications is essential to maintain their efficacy and safety. Ivermectin Orion tablets should be stored under the following conditions:
- Temperature: Store below 25°C (77°F). Do not freeze. Avoid exposing the tablets to excessive heat or direct sunlight.
- Packaging: Keep the tablets in the original blister pack or container to protect from light and moisture. Only remove the tablet from its packaging when you are ready to take it.
- Children: Keep this medicine out of the sight and reach of children. Store in a secure location.
- Expiry date: Do not use Ivermectin Orion after the expiry date printed on the packaging (indicated as “EXP”). The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
If you notice any change in the appearance of the tablets (such as discolouration, crumbling, or unusual odour), do not use them and consult your pharmacist. Medications that have been stored improperly or past their expiry date may be less effective or potentially harmful.
What Does Ivermectin Orion Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Each Ivermectin Orion 3 mg tablet contains:
- Active substance: Ivermectin 3 mg per tablet. Ivermectin is a semi-synthetic derivative of avermectin B1, produced by fermentation of Streptomyces avermitilis. It consists of a mixture of at least 80% avermectin B1a and no more than 20% avermectin B1b. Both components contribute to the antiparasitic activity.
- Microcrystalline cellulose: A commonly used tablet filler and binder that helps give the tablet its structure.
- Pregelatinised maize starch: Acts as a binder and disintegrant, helping the tablet break apart in the gastrointestinal tract for absorption. Derived from maize (corn).
- Citric acid monohydrate: Used as an acidifying and stabilising agent.
- Butylated hydroxyanisole (BHA, E320): An antioxidant that prevents degradation of the active ingredient. Note: BHA may cause local skin reactions (e.g., contact dermatitis) or irritation to the eyes and mucous membranes in sensitive individuals.
- Magnesium stearate: A lubricant that prevents the tablet mixture from sticking to manufacturing equipment during production.
Ivermectin Orion 3 mg tablets are round, white to off-white, and are scored on one side to facilitate dose adjustment where necessary (though the scored line is not intended for halving the tablet for dose splitting). They are typically packaged in aluminium/PVC blister packs.
The pharmaceutical form is designed for oral administration only. Do not crush, chew, or dissolve the tablets unless specifically instructed by your doctor. Swallow the tablets whole with a sufficient amount of water.
Ivermectin Orion contains butylated hydroxyanisole (E320), which may cause skin reactions in sensitive individuals. The tablet also contains maize starch, which is generally considered safe for patients with coeliac disease or gluten intolerance, as the manufacturing process removes gluten proteins. If you have any known allergies to pharmaceutical excipients, discuss this with your doctor or pharmacist before starting treatment.
Frequently Asked Questions About Ivermectin Orion
Ivermectin is an antiparasitic drug derived from avermectins, which are natural compounds produced by the soil bacterium Streptomyces avermitilis. It was discovered in the late 1970s by Satoshi Omura (who isolated the bacterium) and William C. Campbell (who developed its antiparasitic applications). First approved for veterinary use in 1981 and for human use in 1987, ivermectin has since been administered to hundreds of millions of people worldwide. The discovery was recognised with the 2015 Nobel Prize in Physiology or Medicine for its transformative impact on diseases caused by roundworm parasites.
Ivermectin Orion should be taken on an empty stomach with a full glass of water, at least 2 hours before or after food. Studies have shown that taking ivermectin with a high-fat meal can increase its absorption by approximately 2.5-fold, which may alter plasma concentrations beyond the intended therapeutic range. Taking it on an empty stomach ensures more consistent and predictable drug levels. This is particularly important because clinical trials that established the efficacy and safety of ivermectin were conducted under fasting conditions.
Ivermectin reaches peak blood levels approximately 4 hours after oral administration and begins to act on parasites promptly. For scabies, improvement in itching typically occurs within 1–2 weeks, though the mites are usually killed within 24–48 hours of dosing. For strongyloidiasis, stool examinations typically become negative within 1–2 weeks after treatment. For onchocerciasis, microfilarial counts begin declining within days, with maximum reduction seen at 1–3 months post-treatment. The half-life of ivermectin is approximately 18 hours.
Topical ivermectin (as a cream) is approved in several countries for the treatment of rosacea (a chronic inflammatory skin condition). However, the oral formulation (Ivermectin Orion) is specifically approved for parasitic infections. Ivermectin has been studied for various other conditions in research settings, but the approved and evidence-based indications remain focused on parasitic diseases. Always use ivermectin only as prescribed by your doctor for an approved or well-established off-label indication.
The Mazzotti reaction is an inflammatory response that occurs when microfilariae (larval parasites) die in the body, particularly during treatment of onchocerciasis. Symptoms include fever, itching, rash, swollen lymph nodes, joint and muscle pain, rapid heartbeat, and low blood pressure. The reaction is not an allergy to ivermectin itself but rather the body’s immune response to dead and dying parasites. It is usually self-limiting and resolves within a few days. Mild reactions are common and can be managed with supportive care. Severe reactions are rare but may require medical attention, especially if there is significant hypotension or breathing difficulty.
All information on this page is based on international medical guidelines and peer-reviewed research: the WHO Model List of Essential Medicines (2023), EMA Summary of Product Characteristics for ivermectin-containing products, FDA prescribing information for Stromectol, the British National Formulary (BNF), and published systematic reviews including Cochrane reviews on ivermectin for parasitic infections. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials and meta-analyses.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Summary of Product Characteristics: Ivermectin. Amsterdam: EMA; 2025.
- U.S. Food and Drug Administration (FDA). Stromectol (Ivermectin) Prescribing Information. Silver Spring: FDA; 2024.
- Joint Formulary Committee. British National Formulary (BNF): Ivermectin. London: BMJ Group and Pharmaceutical Press; 2025.
- Campbell WC. Ivermectin and Abamectin. Springer-Verlag; 1989. The landmark monograph on avermectin development.
- Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends in Parasitology. 2014;30(9):445–455.
- Rosenberg A, Ngala R, Tettey P, et al. Safety of ivermectin in Loa loa co-endemic areas: a systematic review. PLoS Neglected Tropical Diseases. 2021;15(4):e0009354.
- Mectizan Donation Program. Annual Report 2023: Over 4 Billion Treatments Donated. Atlanta: Task Force for Global Health; 2023.
- Cochrane Infectious Diseases Group. Ivermectin for treating scabies. Cochrane Database of Systematic Reviews. 2023.
- Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database of Systematic Reviews. 2016;(1):CD007745.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising specialists in infectious disease, tropical medicine, and clinical pharmacology.
Medical Writer
iMedic Medical Editorial Team – Specialising in pharmacology, infectious disease, and evidence-based medicine
Medical Reviewer
iMedic Medical Review Board – Independent panel of physicians reviewing content according to WHO, EMA, and FDA guidelines
Pharmacological Review
Clinical Pharmacology Specialist – Drug interactions, dosage accuracy, and pharmacokinetic data verification
Accessibility Review
WCAG 2.2 AAA compliance verified – Screen reader optimised, keyboard navigable, high contrast support
Evidence standard: All content follows the GRADE evidence framework. Medical claims are supported by Level 1A evidence from systematic reviews and meta-analyses of randomised controlled trials. This article has no commercial funding or pharmaceutical industry sponsorship.